Aurinia Pharmaceuticals
AUPH
192 hedge funds and large institutions have $223M invested in Aurinia Pharmaceuticals in 2022 Q4 according to their latest regulatory filings, with 35 funds opening new positions, 55 increasing their positions, 49 reducing their positions, and 30 closing their positions.
109% more call options, than puts
Call options by funds: $11.5M | Put options by funds: $5.52M
17% more first-time investments, than exits
New positions opened: 35 | Existing positions closed: 30
12% more repeat investments, than reductions
Existing positions increased: 55 | Existing positions reduced: 49
2% more funds holding
Funds holding: 189 → 192 (+3)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
3.11% less ownership
Funds ownership: 39.41% → 36.31% (-3.1%)
47% less capital invested
Capital invested by funds: $421M → $223M (-$198M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$24.8M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$12.7M |
| 3 |
WP
Woodline Partners
San Francisco,
California
|
+$7.11M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$5.96M |
| 5 |
Renaissance Technologies
New York
|
+$5.33M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$31.1M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$29M |
| 3 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
-$9.03M |
| 4 |
Stifel Financial
St. Louis,
Missouri
|
-$3.73M |
| 5 |
Barclays
London,
United Kingdom
|
-$3.44M |
AUPH Hedge Fund Activity: Q4 2022 in Review
192 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Aurinia Pharmaceuticals (AUPH) for Q4 2022, worth a combined $223M — down 47% from $421M a quarter earlier.
Buyers outnumbered sellers: 35 funds opened new AUPH positions and 30 closed out — a net gain of 5 holders — while 55 added to existing stakes and 49 trimmed.
The largest buyer was Armistice Capital, adding an estimated $24.8M. The largest seller was Deep Track Capital, cutting an estimated $31.1M.
- 192 institutional investors held Aurinia Pharmaceuticals (AUPH) as of Q4 2022, up from 189 in Q3 2022.
- Funds reported $223M of Aurinia Pharmaceuticals stock for Q4 2022, down 47% quarter-over-quarter.
- 35 funds opened new Aurinia Pharmaceuticals positions in Q4 2022 and 30 closed out, a net change of +5 holders.
- The largest Aurinia Pharmaceuticals buyer in Q4 2022 was Armistice Capital, an estimated $24.8M added.
- The largest Aurinia Pharmaceuticals seller in Q4 2022 was Deep Track Capital, an estimated $31.1M sold.
Based on aggregated 13F filings for Q4 2022.